유전성 암 검사 시장 규모, 점유율, 동향 분석 보고서 : 암별, 기술별, 검사 유형별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Hereditary Cancer Testing Market Summary

The global hereditary cancer testing market size was estimated at USD 4.67 billion in 2024 and is projected to reach USD 14.45 billion by 2033, growing at a CAGR of 13.76% from 2025 to 2033. The demand for hereditary cancer testing is increasing due to technological advancements in genetic testing for cancer detection, integration with precision medicine, and growing awareness through public and government initiatives.

In addition, the rising prevalence of cancer diseases amongst the population is augmenting the adoption of hereditary cancer testing. According to the National Cancer Institute, hereditary cancer, caused by inherited genetic changes, accounts for 10% of all other cancer types. Hereditary cancer is passed on to coming generations as defective familial mutations in the genes, concomitantly increasing the risk of cancer. Hence, there arises a growing need among the people for early detection and for mitigating cancer symptoms.

Advancements in genetic testing technologies, particularly next-generation sequencing (NGS), have significantly improved the accuracy and accessibility of hereditary cancer testing. Traditional methods lack efficiency and are time-consuming, which may prolong the treatment duration thereafter. One such testing technology is the next-generation sequencing (NGS), which can simultaneously detect millions of copies of DNA in a gene within a short span of time, allowing comprehensive profiling of multiple genes and mutations in a single test. For example, Illumina's NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of diseases. The innovations in genetic testing facilitate early detection of hereditary cancer mutations, guide personalized treatment plans, and monitor disease progression non-invasively. Thus, progress in oncology medicine by integration of early cancer detection systems is transforming the perspective to advanced technologies rather than traditional testing methods.

Hereditary testing plays a pivotal role in precision medicine by enabling the identification of genetic mutations that influence cancer risk and treatment response. The basis of precision medicine lies in understanding the effects of alterations in certain genes in cancer. Precision medicine is transforming cancer care to tailor tests and treatments based on individual patient characteristics. It helps identify people at high risk for cancer, allowing early interventions to reduce their risk. It also aids in detecting certain cancers at an early stage and ensures accurate diagnosis of specific cancer types. Additionally, it allows ongoing evaluation of how well a treatment is working, enabling adjustments to improve outcomes. This personalized approach improves survival rates and quality of life for cancer patients by moving beyond one-size-fits-all therapies to targeted, patient-specific care.

Growing awareness through public and government initiatives plays a crucial role in expanding hereditary cancer testing. Government efforts, for example, in February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN), a clinical trials network aimed at evaluating emerging cancer screening technologies, including multi-cancer detection (MCD) tests. This initiative supports the Biden-Harris administration's Cancer Moonshot by focusing on identifying cancers earlier, when treatment is more effective.

The National Institutes of Health (NIH) is also working continuously in prevention and screening for five major types of cancer: breast, cervical, colorectal, lung, and prostate, in order to save lives. Due to its initiatives, as of December 2024, 4.75 million deaths have been averted. Furthermore, several campaigns and online resources have raised awareness among the people for hereditary cancer testing. These combined efforts aim to empower individuals with knowledge, encourage timely testing, and support preventive care, ultimately reducing cancer incidence and improving outcomes across diverse populations.

Global Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hereditary cancer testing market report based on cancer, technology, test type, end use, and region:

• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Ovarian Cancer
• Prostate Cancer
• Stomach/Gastric Cancer
• Melanoma
• Sarcoma
• Uterine Cancer
• Pancreatic Cancer
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Cytogenetic
• Biochemical
• Molecular Testing
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Predictive Testing
• Diagnostic Testing
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic Centers
• Hospitals
• Clinics
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Cancer
  • 1.2.2. Technology
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Cancer outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Test Type outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Hereditary Cancer Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements of genetic testing in cancer detection
    • 3.2.1.2. Integration with precision medicine
    • 3.2.1.3. Growing awareness through public and government initiatives
    • 3.2.1.4. Rising prevalence of cancer
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs and limited insurance coverage
• 3.3. Hereditary Cancer Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Hereditary Cancer Testing Market: Cancer Movement Analysis
• 4.3. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2021 to 2033 (USD Million)
• 4.4. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Lung Cancer
  • 4.5.1. Lung Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Breast Cancer
  • 4.6.1. Breast Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Colorectal Cancer
  • 4.7.1. Colorectal Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Cervical Cancer
  • 4.8.1. Cervical Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.9. Ovarian Cancer
  • 4.9.1. Ovarian Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.10. Prostate Cancer
  • 4.10.1. Prostate Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.11. Stomach/Gastric Cancer
  • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.12. Melanoma
  • 4.12.1. Melanoma Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.13. Sarcoma
  • 4.13.1. Sarcoma Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.14. Uterine Cancer
  • 4.14.1. Uterine Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.15. Pancreatic Cancer
  • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.16. Others
  • 4.16.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Hereditary Cancer Testing Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Cytogenetic
  • 5.5.1. Cytogenetic Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Biochemical
  • 5.6.1. Biochemical Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Molecular Testing
  • 5.7.1. Molecular Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis

• 6.1. Test type Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Test type Market by Capacity Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Predictive Testing
  • 6.5.1. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Diagnostic Testing
  • 6.6.1. Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2033
• 7.2. Segment Dashboard
• 7.3. Global End Use Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Diagnostic Centers
  • 7.5.1. Diagnostic Centers Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Hospitals
  • 7.6.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Clinics
  • 7.7.1. Clinics Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.5. North America
  • 8.5.1. North America: SWOT Analysis
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/Reimbursement
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/Reimbursement
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/Reimbursement
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe: SWOT Analysis
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/Reimbursement
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/Reimbursement
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/Reimbursement
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/Reimbursement
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/Reimbursement
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/Reimbursement
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/Reimbursement
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework/Reimbursement
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific: SWOT Analysis
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/Reimbursement
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/Reimbursement
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/Reimbursement
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/Reimbursement
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/Reimbursement
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/Reimbursement
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America: SWOT Analysis
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/Reimbursement
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/Reimbursement
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA: SWOT Analysis
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/Reimbursement
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/Reimbursement
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/Reimbursement
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2024
  • 9.3.4. Myriad Genetics, Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Services benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Invitae Corporation
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Services benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Bio-Rad Laboratories
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Services benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. CSL Ltd
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Services benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Qiagen NV
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Services benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Danaher Corporation
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Services benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Thermo Fisher Scientific
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Services benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Abbott Laboratories
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Services benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. EUROFINS SCIENTIFIC
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Services benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. F. HOFFMANN-LA ROCHE LTD
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Services benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Illumina, Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Services benchmarking
    • 9.3.14.4. Strategic initiatives